Literature DB >> 11463019

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

B R Edlin1, K H Seal, J Lorvick, A H Kral, D H Ciccarone, L D Moore, B Lo.   

Abstract

Entities:  

Keywords:  Health Care and Public Health; Professional Patient Relationship

Mesh：

Substances：

Year:  2001        PMID： 11463019      PMCID： PMC1510901          DOI： 10.1056/NEJM200107193450311

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  36 in total

1.  The effect of syringe exchange use on high-risk injection drug users: a cohort study.

Authors:  R N Bluthenthal; A H Kral; L Gee; E A Erringer; B R Edlin
Journal:  AIDS       Date:  2000-03-31       Impact factor: 4.177

Review 2.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Authors: 
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

3.  Peginterferon alfa-2a in patients with chronic hepatitis C.

Authors:  S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

Review 4.  Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

Authors:  E Dieperink; M Willenbring; S B Ho
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

5.  Epidemiology of hepatitis C in the United States.

Authors:  I Williams
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

6.  Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.

Authors:  J P Moatti; M P Carrieri; B Spire; J A Gastaut; J P Cassuto; J Moreau
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

Review 7.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

Review 8.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

9.  Helping the urban poor stay with antiretroviral HIV drug therapy.

Authors:  J D Bamberger; J Unick; P Klein; M Fraser; M Chesney; M H Katz
Journal:  Am J Public Health       Date:  2000-05       Impact factor: 9.308

10.  Physician prescribing of sterile injection equipment to prevent HIV infection: time for action.

Authors:  S Burris; P Lurie; D Abrahamson; J D Rich
Journal:  Ann Intern Med       Date:  2000-08-01       Impact factor: 25.391
View more
  57 in total

1.  Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).

Authors:  Benedikt Fischer; Jürgen Rehm; Suzanne Brissette; Serge Brochu; Julie Bruneau; Nady El-Guebaly; Lina Noël; Mark Tyndall; Cameron Wild; Phil Mun; Dolly Baliunas
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

2.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

3.  Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program.

Authors:  Robert J Roose; Lauren Cockerham-Colas; Irene Soloway; Abigail Batchelder; Alain H Litwin
Journal:  J Health Care Poor Underserved       Date:  2014-05

4.  Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.

Authors:  Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

5.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

6.  Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings.

Authors:  Sean M Murphy; Dana Dweik; Sterling McPherson; John M Roll
Journal:  Am J Drug Alcohol Abuse       Date:  2015-01       Impact factor: 3.829

7.  Debating Medical Utility, Not Futility: Ethical Dilemmas in Treating Critically Ill People Who Use Injection Drugs.

Authors:  Stephen R Baldassarri; Ike Lee; Stephen R Latham; Gail D'Onofrio
Journal:  J Law Med Ethics       Date:  2018-06       Impact factor: 1.718

8.  Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Authors:  Michael Gschwantler; Hermann Laferl; Wolfgang Vogel; Wolfgang Korak; Stephan Moser; Harald Hofer; Bernhard Bauer; Michael Schleicher; Barbara Bognar; Martin Bischof; Rudolf Stauber; Andreas Maieron; Peter Ferenci
Journal:  Wien Klin Wochenschr       Date:  2017-09-12       Impact factor: 1.704

9.  Morphine enhances hepatitis C virus (HCV) replicon expression.

Authors:  Yuan Li; Ting Zhang; Steven D Douglas; Jian-Ping Lai; Wei-Dong Xiao; David E Pleasure; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  HIV/hepatitis prevention in drug abuse treatment programs: guidance from research.

Authors:  James L Sorensen; Carmen L Masson; David C Perlman
Journal:  Sci Pract Perspect       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.